PGT-A – Embryo Chromosomal Abnormalities Test

A genetic test designed to increase the chance of IVF success

PGT-A, or preimplantation genetic testing for aneuploidies, is the process of screening IVF embryos for chromosome abnormalities prior to transfer, with the goal of increasing the likelihood of achieving a successful pregnancy. PGT-A was formerly known as PGS, preimplantation genetic screening.

PGT-A has been shown to:

  • Increase implantation rates
  • Reduce miscarriage rates
  • Increase ongoing pregnancy rates
  • Increase live birth rates
  • Reduce the time to pregnancy
  • Enable confident single embryo transfer


Our innovative PGTaiSM technology platform is clinically launched in the USA, Canada, UK and Ireland only.
Our PGT-A product is available for sale in selected countries.

Contact Us For More Information

Technology plays a central role in PGT-A

More advanced technology has been shown to produce more reliable results.

Over the years, advances in technology have played a pivotal role in the evolution of PGT. These technological innovations have driven improvements in accuracy, sensitivity and specificity of PGT-A results.

We are proud to announce the next leap in PGT-A technology. Our esteemed scientific experts have developed a revolutionary new platform in PGT-A analysis and reporting.

CooperGenomics PGT-A is performed via Next-Generation Sequencing technology and provides the best detection of:

  • Aneuploidy
  • Partial (segmental) aneuploidy
  • Unbalanced translocations
  • Some polyploidies
  • Mosaicism

Introducing PGTaiSM

CooperGenomics’ revolutionary approach to PGT-A

A new PGT-A interpretation and reporting platform

The PGTaiSM technology platform is a ground-breaking, first of its kind algorithm that harnesses the power of big data, machine learning and artificial intelligence to maximize PGT-A calling, interpretation and reporting.

Learn More About PGTai


Benefits of PGT-A

PGT-A has been shown to increase implantation rates, reduce miscarriage rates, and increase live birth rates. PGT-A also enables more confident single embryo transfer, reducing the risk of complications associated with twin or triplet pregnancies.

PGT-A reduces miscarriage rates


PGT-A increases live birth rates


Sample size (number of transfers)4

<35 35-37 38-40 41-42 >42
IVF without PGT-A 29,989 13,144 10,497 4,678 3,009
IVF with PGT-A 5,326 3,366 2,941 973 243

The PGT-A Process

PGT-A can be seamlessly added to IVF to help increase the chances of cycle success. PGT-A typically requires that embryos are frozen prior to transfer. Genetic counselors are available to inform, support, and guide families throughout the process.


Aneuploidy and Age

All patients are at risk of producing chromosomally abnormal embryos. As a woman ages, the risk of producing aneuploid embryos significantly increases.

PGT-A Results Distribution

Internal CooperGenomics data of blastocyst biopsies tested via Next Generation Sequencing (2014-2017)

Unlike aneuploidy, mosaicism is thought to be independent of maternal age. However, the number of embryos clinically classified as mosaic decreases slightly with age, as shown here. This is due to the increased liklihood that an embryo with a mosaic abnormality will also have a meiotic aneuploidy, which would result in that embryo being classified as ‘aneuploid’ rather than ‘mosaic’.


Mosaicism occurs when an embryo contains both euploid and aneuploid cells as a result of errors in cell division (mitosis) made during embryo growth. With the advent of high-resolution PGT-A technology, mosaicism has emerged alongside euploidy and aneuploidy as a third category of potential PGT-A results.

Unlike traditional PGT-A technologies, CooperGenomics’ PGT-A  has been validated to reliably detect mosaic samples with 20-80% aneuploid cells. While more research is required to fully understand the clinical implications of embryonic mosaicism, current studies show that mosaic embryos implant less and miscarry more than euploid embryos, but some mosaic embryos maintain their viability and can lead to live birth. Given that, experts recommend considering mosaic embryos for transfer in cases where no euploid embryos are available and prioritizing mosaics based on the level of aneuploidy and chromosome impacted.


Our team is pioneering cutting-edge research and contributing to key scientific discussions and publications to drive a better understanding of the impact of mosaicism.

Reporting and Counseling

PGT-A reports are typically available within 14 days of sample receipt at a CooperGenomics laboratory, though we are happy to work with your team to accommodate next day results for fresh transfers, given prior notice. Reports are released to the ordering provider, with results clearly presented on the first page(s) and euploid/normal results highlighted. We are proud to be one of the first laboratories standardly reporting mosaic results, categorized as low-level mosaic, high-level mosaic, or complex abnormal.

CooperGenomics’ expert team of specially trained, board-certified genetic counselors is available for you and your patients at every point in the PGT-A testing process.

Introducing PGT Simplified

CooperGenomicsSM brings you and your patients a better PGT experience


Learn More About EngagedMD
1. Harton et al. (2013) Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertil Steril.
2. Fragouli et al. (2015) The developmental potential of mosaic embryos. Fertil Steril.
3. Greco et al. (2015) Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. N Engl J Med.